Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Document › Details

CureVac B.V.. (8/10/20). "Press Release: CureVac Announces Proposed Initial Public Offering of Common Shares". Tübingen.

Organisations Organisation CureVac B.V. (Nasdaq: CVAC)
  Organisation 2 Bank of America Securities LLC (BofA Securities)
Products Product mRNA technology
  Product 2 investment banking
Index term Index term CureVac–SEVERAL: investment, 202008 IPO $245.3m with 13.3m+2m common shares at $16/share at Nasdaq Global Market
Persons Person Fakih, Sarah (CureVac 202007– VP Investor Relations before MorphoSys + Qiagen)
  Person 2 Schüller, Thorsten (CureVac 201911 Corporate Communications)
     


CureVac B.V. (“CureVac” or the “Company”), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today that it intends to offer and sell in an underwritten public offering of 13,333,333 common shares. In addition, the Company expects to grant the underwriters a 30-day option to purchase up to an additional 1,999,999 common shares at the initial public offering price, less underwriting discounts and commissions. All the shares will be offered by CureVac. The initial public offering price is expected to be between $14.00 and $16.00 per common share. CureVac has applied to list its common shares on The Nasdaq Global Market under the ticker symbol “CVAC”.

BofA Securities, Jefferies and Credit Suisse are acting as joint book-running managers for the proposed offering, with Berenberg and Kempen & Co acting as passive book-running managers.

CureVac intends to use the net proceeds from the offering and a concurrent private placement, together with cash and cash equivalents on hand, as follows: (i) to fund the Company’s mRNA vaccine program against SARS-CoV-2 through the completion of Phase 3; (ii) to fund the expansion of the Company’s short term manufacturing capabilities; (iii) to advance the Company’s lead oncology program, CV8102, through the completion of the Phase 2 clinical trial; (iv) to advance the Company’s vaccine program, CV7202 in rabies through the completion of the Phase 2 clinical trial and (v) to invest in further development of the Company’s mRNA technology platform and to advance the development of other preclinical and clinical programs.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission (SEC), but has not yet become effective. The securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective.

The offering is being made only by means of a prospectus. Copies of the preliminary prospectus relating to the offering may be obtained, when available, for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the preliminary prospectus, when available, may be obtained from BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, by telephone at (800) 299-1322 or by email at dg.prospectus_requests@bofa.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; and Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, North Carolina 27560, by telephone at (800) 221-1037 or by email at usa.prospectus@credit-suisse.com. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.


About CureVac

CureVac is a global clinical-stage biopharmaceutical company in the field of messenger RNA (mRNA) technology with expertise in developing and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of prophylactic vaccines, cancer therapies, antibody therapies and the treatment of protein therapies. CureVac is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA.


CureVac Investor Relation Contact

Dr. Sarah Fakih, Vice President Investor Relations
CureVac, Tübingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949
sarah.fakih@curevac.com


CureVac Media Contact

Thorsten Schüller, Director Corporate Communications
CureVac, Tübingen, Germany
T: +49 7071 9883-1577
thorsten.schueller@curevac.com

   
Record changed: 2020-08-12

Advertisement

Picture [iito] Plain Stupid Simple 650x80px

More documents for CureVac B.V. (Nasdaq: CVAC)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [iito] No Content Marketing 650x80px




» top